Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955142 | 0.91 | TAAR1 (0.82) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL955372 | 0.89 | TAAR1 (0.80) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL951672 | 0.89 | TAAR1 (0.80) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL954615 | 0.87 | TAAR1 (0.76) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL954511 | 0.81 | TAAR1 (0.68) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL955275 | 0.80 | TAAR1 (0.66) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL957081 | 0.80 | TAAR1 (0.66) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL956432 | 0.80 | TAAR1 (0.66) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL953782 | 0.79 | TAAR1 (1.00) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL955485 | 0.78 | TAAR1 (0.63) | TAAR1HTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | disclosed |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TAAR1 1/4885HTR1A 35/4885ADRA2A 6/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TAAR1 1/4885HTR1A 42/4885ADRA2A 6/4885 |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | TAAR1 716/4885HTR1A 3047/4885ADRA2A 1347/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | TAAR1 748/4885HTR1A 3138/4885ADRA2A 1353/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885HTR1A 15/4885ADRA2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.